Expert Insights on Key Data From ASH 2020 on Acute and Chronic Leukemias - a podcast by Clinical Care Options

In this episode, Jorge Cortes, MD, and Eunice S. Wang, MD, discuss the clinical implications of 3 key studies in acute myeloid leukemia (AML) and chronic myeloid leukemia (CML) presented at the virtual ASH 2020 annual conference. Topics include:  

• The macrophage immune checkpoint inhibitor magrolimab in AML
• The STAMP inhibitor asciminib in CML (the ASCEMBL trial)
• Optimal dosing for the TKI ponatinib in CML

Presenters:

Jorge Cortes, MD
Director, Georgia Cancer Center
Eminent Scholar, Georgia Research Academy
Augusta, Georgia

Eunice S. Wang, MD
Professor, Oncology
Chief, Leukemia Service
Department of Medicine
Roswell Park Comprehensive Cancer Center
Buffalo, New York

Content supported by educational grants from Amgen; AstraZeneca; Bristol-Myers Squibb; Epizyme, Inc; GlaxoSmithKline; Incyte Corporation; Janssen Biotech; Karyopharm Therapeutics Inc; Novartis; PharmaEssentia Corp; Seattle Genetics; and Takeda Oncology.

Link to full program and Capsule Summary downloadable slidesets:
https://bit.ly/3tyQ9nG

 

Further episodes of CCO Oncology Podcast

Further podcasts by Clinical Care Options

Website of Clinical Care Options